Skip to content
Therapy But Better – Lifestyle
Author:
Humacyte, Inc
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
November 19, 2026
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
November 16, 2026
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
November 11, 2026
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
November 10, 2026
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
November 9, 2026
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
November 3, 2026
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
November 2, 2026
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
October 28, 2026
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
October 23, 2026
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
October 15, 2026
1
2
3
Next Page
→